Minority Human Immunodeficiency Virus Type 1 Variants in Antiretroviral-Naive Persons with Reverse Transcriptase Codon 215 Revertant Mutations
- 1 November 2008
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 82 (21) , 10747-10755
- https://doi.org/10.1128/jvi.01827-07
Abstract
T215 revertant mutations such as T215C/D/E/S that evolve from the nucleoside reverse transcriptase (RT) inhibitor mutations T215Y/F have been found in about 3% of human immunodeficiency virus type 1 (HIV-1) isolates from newly diagnosed HIV-1-infected persons. We used a newly developed sequencing method-ultradeep pyrosequencing (UDPS; 454 Life Sciences)-to determine the frequency with which T215Y/F or other RT inhibitor resistance mutations could be detected as minority variants in samples from untreated persons that contain T215 revertants ("revertant" samples) compared with samples from untreated persons that lack such revertants ("control" samples). Among the 22 revertant and 29 control samples, UDPS detected a mean of 3.8 and 4.8 additional RT amino acid mutations, respectively. In 6 of 22 (27%) revertant samples and in 4 of 29 control samples (14%; P = 0.4), UDPS detected one or more RT inhibitor resistance mutations. T215Y or T215F was not detected in any of the revertant or control samples; however, 4 of 22 revertant samples had one or more T215 revertants that were detected by UDPS but not by direct PCR sequencing. The failure to detect viruses with T215Y/F in the 22 revertant samples in this study may result from the overwhelming replacement of transmitted T215Y variants by the more fit T215 revertants or from the primary transmission of a T215 revertant in a subset of persons with T215 revertants.This publication has 34 references indexed in Scilit:
- Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapyAIDS, 2008
- Preexisting Resistance to Nonnucleoside Reverse‐Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz‐Based Regimen in Treatment‐Naive HIV‐1–Infected SubjectsThe Journal of Infectious Diseases, 2008
- Baseline Genotype as a Predictor of Virological Failure to Emtricitabine or Stavudine in Combination with Didanosine and EfavirenzAIDS Research and Human Retroviruses, 2007
- Accuracy and quality of massively parallel DNA pyrosequencingGenome Biology, 2007
- Characterization of mutation spectra with ultra-deep pyrosequencing: Application to HIV-1 drug resistanceGenome Research, 2007
- Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational studyBMJ, 2005
- Genome sequencing in microfabricated high-density picolitre reactorsNature, 2005
- Underestimation of HIV Type 1 Drug Resistance Mutations: Results from the ENVA-2 Genotyping Proficiency ProgramAIDS Research and Human Retroviruses, 2002
- High Degree of Interlaboratory Reproducibility of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Sequencing of Plasma Samples from Heavily Treated PatientsJournal of Clinical Microbiology, 2001
- Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencingNature, 1993